ACADIA Pharmaceuticals Inc. Net Debt

Net Debt of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt growth rates and interactive chart. Net debt is the sum of all interest-bearing debt (short-term and long-term) minus cash and short-term investments. A positive number indicates the company's total debt exceeds its cash and short-term investments balances, while a negative number means the company has more cash than its total debt. This figure is also used in Enterprise value calculation.


Highlights and Quick Summary

  • Net Debt for the quarter ending March 30, 2021 was $-517 Million (a -11.2% decrease compared to previous quarter)
  • Year-over-year quarterly Net Debt decreased by -20.46%
  • Annual Net Debt for 2020 was $-582 Million (a -15.3% decrease from previous year)
  • Annual Net Debt for 2019 was $-688 Million (a 45.22% increase from previous year)
  • Annual Net Debt for 2018 was $-474 Million (a 38.72% increase from previous year)
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt of ACADIA Pharmaceuticals Inc.

Most recent Net Debtof ACAD including historical data for past 10 years.

Interactive Chart of Net Debt of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Net Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-517.19
2020 $-582.41 $-595.24 $-650.23 $-642.41 $-582.41
2019 $-687.63 $-677.47 $-375.15 $-407.57 $-687.63
2018 $-473.52 $-214.14 $-256.86 $-298.06 $-473.52
2017 $-341.34 $-366.63 $-417.32 $-469.48 $-341.34
2016 $-528.88 $-588.86 $-412.36 $-457.03 $-528.88
2015 $-215.13 $-240.45 $-270.78 $-297.68 $-215.13
2014 $-322.49 $-337.78 $-354.45 $-369.29 $-322.49
2013 $-185.78 $-196.18 $-205.45 $-101.46 $-185.78
2012 $-107.97 $-23.06 $-21.34 $-25.9 $-107.97
2011 $-31.02 $-36.11 $-40.32 $-45.62 $-31.02
2010 $-37.01 $-32.07 $-34.06 $-37.01

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.